Related Experiment Video
Updated: May 14, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations
1Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris & Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.
No abstract available in PubMed .
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
